,
your personalized virtual assistant to find clinical trials. Go head, 
Nikhil Munshi, MD
Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 Dana FarberBoston, Massachusetts - 02115 Dana Faber Cancer InstituteBoston, Massachusetts - 02115 Massachusetts General HospitalBoston, Massachusetts - 02114 Dana-Farber Cancer Institute/Brigham & Women's ...Boston, Massachusetts - 02115 |
- CLINICAL TRIALS 7
- CONDITIONS4
- INTERVENTIONS12
- SINCE2005
Blockage of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
March 2010 - March 2013
Study on the Anti-tumor Activity Safety and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First Relapse
September 2010 - March 2014
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
January 2009 - November 2010
Bortezomib Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
August 2006 - August 2010
Study on the Anti-tumor Activity Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
September 2010 - September 2013
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
October 2007 - October 2010
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
April 2005 - September 2011
Multiple Myeloma
Neoplasms, Plasma Cell
Bone Diseases
Recurrence
Placebo
Zoledronic Acid
Lenalidomide
Ct-011
Dendritic Cell Fusion Vaccine
Bortezomib
Dexamethasone
Iph2101 Combined To Lenalidomide
Bhq880
Iph2101 0.2 Mg/Kg
Iph2101 2 Mg/Kg
Dendritic Cell Tumor Fusion
